Glycogen synthase kinase-3 (GSK-3) is a multi-functional kinase that regulates signalling pathways affecting glycogen metabolism, protein synthesis, mitosis, and apoptosis. GSK-3 inhibition limits cardiac ischaemia-reperfusion (IR) injury, but mechanisms are not clearly defined. This study tested the hypothesis that acute GSK-3 inhibition stimulates glycogen synthesis, repartitions glucose away from glycolysis, reduces proton (H þ ) production from glucose metabolism, and attenuates intracellular Ca 2þ (Ca 2þ i ) overload.
Introduction
Glycogen synthase kinase-3 (GSK-3) is a multi-functional kinase that regulates signalling pathways affecting glycogen metabolism, protein synthesis, mitosis and apoptosis. It has 2 isoforms, a and b, that possess strong homology in their kinase domains. 1 GSK-3 is constitutively active and is regulated by inhibitory phosphorylation by upstream kinases on Ser9 (b isoform) or Ser21 (a isoform). 2 In heart, GSK-3 has several important roles. It actively inhibits hypertrophy and its inhibition stimulates development of cardiac hypertrophy. 3 Recently, inhibition of GSK-3 during ischaemia and reperfusion (IR) has been implicated as a cardioprotective mechanism. Tong et al. 4 first reported that infarct size reduction by ischaemic preconditioning is due to increased GSK-3 phosphorylation and its subsequent inhibition. Furthermore, inhibition of GSK-3 was suggested as a mechanism explaining cardioprotection induced by postconditioning, 5 opioids, 6 bradykinin, 7 erythropoietin, 8 adenosine A 3 receptor activation, 9 isoflurane, 10 and PKCd inhibition. 11 However, mechanisms mediating these beneficial effects of GSK-3 inhibition are not fully understood. One proposed mechanism involves prevention of mitochondrial permeability transition pore (mPTP) opening 12 potentially due to effects on the voltage-dependent anion channel (VDAC) 13 or adenine nucleotide translocase (ANT). 14 However, a direct interaction between GSK-3 and the mPTP is still not established. In addition, recent evidence from mitochondria that are deficient in all isoforms of VDAC shows that VDAC is dispensable in mPTP opening. 15 Other proposed mechanisms involve increased glucose utilization 16 and reduced mitochondrial ATP hydrolysis during ischaemia, 17 but these effects are unable to explain the protective effects of GSK-3 inhibition when added at the onset of reperfusion.
Interestingly, although the initial function (and naming) of GSK-3 was related to its effects on glycogen synthase (GS) activity, the contribution of alterations in glycogen or glucose metabolism by GSK-3 inhibition to cardioprotection has not been investigated. GSK-3 phosphorylates GS at Ser640 (site 3a) and Ser 644 (site 3b) via a hierarchal mechanism and thereby inhibits GS activity. 18 In contrast, phosphorylation and inhibition of GSK-3, such as by insulin-mediated activation of the PI3K/Akt pathway, increases GS activity and accelerates glycogen synthesis. 19 Thus, GSK-3 may influence the partitioning of glucose-6phosphate between the pathways of glycogen synthesis and glycolysis.
In this study, we test the hypothesis that inhibition of GSK-3 will stimulate glycogen synthesis, repartition glucose partially away from glycolysis, improve the coupling between glycolysis and glucose oxidation and reduce the potential for intracellular acidosis. As acidosis initiates the intracellular accumulation of Na þ and Ca 2þ by enhanced activities of the Na þ -H þ exchanger (NHE) and reverse-mode Na þ -Ca 2þ exchanger (rmNCX), respectively, 20 we further investigated whether GSK-3 inhibition attenuates Ca 2þ i accumulation during ischaemia and reperfusion.
Methods
An expanded Methods section is available in the online data Supplement at http://cardiovascres.oxfordjournals.org/
Experimental animals
Male Sprague-Dawley rats (350-400 g) were used in this study. All experiments were performed with accordance with the guidelines of the Animal Use and Care Committee, University of Alberta (animal ethics protocol #027). The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Isolated working rat heart perfusion
Rat hearts were cannulated for isolated working mode perfusion in a recirculating system under conditions of constant workload (11.5 mmHg preload, 80 mmHg afterload, rate 5 Hz) as described in detail previously. 21 Left-ventricular (LV) work (in J min 21 g dry wt 21 ) was used as a continuous index of LV mechanical function.
Biochemical measurements 2.3.1 Measurement of rates of energy substrate metabolism
Rates of glycolysis, glucose oxidation, and palmitate oxidation were measured as described previously. 21, 22 Rates of acetyl CoA, ATP, and H þ production were calculated as described previously. 23 
Measurement of glycogen content and glycogen turnover
Myocardial glycogen content (in mmol glucosyl units g dry wt 21 ) was determined as described previously. 21 The amount of radiolabelled glucose in glycogen extracts was also determined to evaluate the degree of incorporation of radiolabelled glucose into glycogen which corresponded to the rate of glycogen synthesis. 24 
Glucose uptake
Glucose uptake (in mmol glucose min 21 g dry wt 21 ) was calculated as described previously 24 as the sum of the rates of glycolysis and the rate of incorporation of radiolabelled glucose into glycogen during each phase of the perfusion protocol.
Measurement of Ca 21 i concentration in working rat hearts
Measurement of Ca 2þ i concentration in working rat hearts was performed as previously described. 25, 26 2.5 Perfusion protocols
Ischaemia-reperfusion protocol
After an initial 45 min of baseline aerobic perfusion, hearts were subjected to 17 min of global ischaemia (GI) followed by 30 min of reperfusion. Hearts used for Ca 2þ i measurements were perfused for 15 min of baseline aerobic perfusion after the indo-1AM loading procedure. This was followed by 20 min of GI and 30 min of reperfusion. These durations of GI were sufficient to cause marked LV dysfunction that is reversible. Longer periods of ischaemia resulted in the failure of the hearts to recover at reperfusion which would have hindered the measurement of the metabolic rates. SB216763 (SB, 3 mmol/L) or vehicle (DMSO, 0.25%) was added either 5 min prior to ischaemia or at the onset of reperfusion. Once added, the drug remained in the recirculating system until the end of the perfusion protocol. This concentration of SB was shown previously to produce sufficient inhibition of GSK-3 and to induce cardioprotection in the isolated perfused rat heart. 4, 17 Higher concentrations of SB (10 mmol/L) did not provide greater cardioprotection (data not shown).
Aerobic protocol
Two series of hearts with different pre-treatment glycogen contents were studied. In the first series, glycogen replete (G-replete, n ¼ 7), myocardial glycogen stores were replenished prior to administration of either SB (3 mmol/L) or vehicle to near the normal level reported for the rat heart in vivo (120-150 mmol g dry wt 21 ). 27 In the second series, glycogen depleted (G-depleted, n ¼ 7), myocardial glycogen stores were depleted non-ischaemically as described previously 21 to a level equivalent to those measured at the onset of reperfusion in the hearts subjected to GI (see Supplementary material online, Figure S1 ).
Statistical analyses
Results are expressed as means + SEM of n observations. The significance of the differences for two group comparisons was estimated by Student's t-test. The significance of difference in time-course experiments was estimated by two-way analysis of variance with repeated measures on time and a Newman -Keuls post-test. Differences were considered statistically significant when P , 0.05.
Results

GSK-3 inhibition enhances recovery of LV mechanical function following ischaemia
Left ventricular mechanical function was stable during the initial period of baseline perfusion with no differences among experimental groups ( Figure 1A) . SB216763 (3 mmol/L) given 5 min before ischaemia significantly enhanced recovery of LV mechanical function to 53.0 + 5.6% (n ¼ 11, P , 0.001) compared with 21.1 + 5.3% (n ¼ 17) in vehicle-treated hearts ( Figure 1B) . This cardioprotective effect of SB is similar to effects observed in previous studies. 4,17
GSK-3 inhibition stimulates glycogen synthesis and reduces glycolysis and H 1 production during reperfusion
SB stimulated the rate of glycogen synthesis as measured by the degree of incorporation of radiolabelled glucose into glycogen by 118% (P , 0.01) ( Figure 2A ). The rate of glycogen synthesis in individual hearts is directly correlated with its post-ischaemic recovery of LV function (r 2 ¼ 0.51, P , 0.005, Figure 4A ), providing evidence of a potential role of enhanced glycogen synthesis in cardioprotection.
Stimulation of glycogen synthesis by SB was associated with repartitioning of glucose-6-phosphate away from glycolysis, causing a 62% inhibition (P , 0.01) relative to vehicle-treated hearts ( Figure 2B ). Evidence for repartitioning of glucose-6-phosphate between these pathways is strengthened by the significant inverse correlation between rates of glycogen synthesis and glycolysis (r 2 ¼ 0.59, P , 0.001) ( Figure 4B) .
Inhibition of GSK-3 also increased rates of glucose ( Figure 2C ) and palmitate oxidation ( Figure 2D ) during reperfusion by 65 and 125%, respectively. There was also a trend (P ¼ 0.053) towards lower rates of glucose uptake in SB-treated hearts ( Figure 2E) . The SB-mediated inhibition of glycolysis and acceleration of glucose oxidation during reperfusion reduced rates of H þ production derived from glucose metabolism by 71% (P , 0.01; Figure 2F ).
The increased rates of glucose and palmitate oxidation during reperfusion in SB-treated hearts resulted in a significant elevation in acetyl CoA and ATP production by 99 and 64%, respectively ( Figure 2G and H ). This increase in ATP production by SB resulted from a higher contribution of palmitate and glucose oxidation, while there was a lower contribution from glycolysis ( Figure 2I ).
Inhibition of GSK-3 attenuates Ca 21 i overload during I/R
To explore further the mechanism by which inhibition of GSK-3 confers cardioprotection, we examined the effect of pre-ischaemic administration of SB on Ca 2þ i levels (Figure 3 ). Both groups show equivalent d[Ca 2þ ] i ( Figure 3D ) as well as s[Ca 2þ ] i ( Figure 3E ) during aerobic baseline perfusion. After 5 min of GI, there was a significant increase in d[Ca 2þ ] i in both groups. In vehicle-treated hearts, d[Ca 2þ ] i continued to increase throughout the remaining period of ischaemia. However, in SB-treated hearts there was a significant attenuation of diastolic Ca 2þ i accumulation after the initial 5 min of GI (by 43% at the end of GI, P , 0.01) ( Figure 3D ). Ca 2þ i transients gradually ceased during GI, so values of s[Ca 2þ ] i were not detectable ( Figure 3E ). During reperfusion, both d[Ca 2þ ] i and s[Ca 2þ ] i recovered only partially in vehicletreated hearts and remained significantly higher than aerobic values. Inhibition of GSK-3 resulted in a significant reduction of both diastolic and systolic Ca 2þ i overload ( Figure 3D and E). This was associated with improved recovery of post-ischaemic LV function to 71.8 + 5.2% of baseline (P , 0.001) relative to 26.7 + 7.1% in vehicle-treated hearts (data not shown). There were no significant differences in Ca 2þ i transient amplitude between groups ( Figure 3F) . Values for d[Ca 2þ ] i during reperfusion show a significant inverse correlation with the degree of recovery of LV function (r 2 ¼ 0.73, P , 0.005, Figure 4C ).
GSK-3 inhibition results in similar reduction in H 1 production under non-ischaemic conditions of glycogen depletion
In order to assess the exact role of the stimulation of glycogen synthesis induced by inhibition of GSK-3, it is important to delineate the cause and effect relationship between glycogen and glucose metabolism and improved LV function during reperfusion. For this purpose, we studied the effects of SB in aerobically perfused hearts (no ischaemia) with normal (G-replete) or partially depleted glycogen stores (G-depleted) (see Supplementary material online, Figure S1 ).
Glycogen-replete hearts
SB had no effect on LV work in G-replete hearts (2.41 + 0.12 vs. 2.44 + 0.25 J min 21 g dry wt 21 ). SB elicited only a minor alteration in the rate of glycogen synthesis that was not significantly different from vehicle-treated hearts ( Figure 5A) . As a result, SB did not alter rates of glycolysis ( Figure 5B) , glucose oxidation ( Figure 5C ), or H þ production ( Figure 5D ) in G-replete hearts.
Glycogen-depleted hearts
SB had no effect on LV work in G-depleted hearts (2.12 + 0.21 vs. 2.07 + 0.14 J min 21 g dry wt 21 ). SB induced a significant increase in the rate of glycogen synthesis in G-depleted hearts by 40% (P , 0.05) ( Figure 5E ) which was accompanied by reduced rates of glycolysis (by 31%, P , 0.005) ( Figure 5F ) and H þ production (by 38%, P , 0.005) ( Figure 5H ). SB did not affect glucose oxidation ( Figure 5G) . These results confirm that inhibition of GSK-3, through its effects on glycogen synthesis, results in the reduction of H þ production independent of LV mechanical function and that these effects are dependent on the level of myocardial glycogen.
Inhibition of GSK-3 protects against reperfusion injury
Administration of SB (3 mmol/L) only at the onset of reperfusion also improved the recovery of LV mechanical function to 66.9 + 7.3% (n ¼ 6, P , 0.0005) compared with 21.1 + 5.3% (n ¼ 17) in vehicle-treated hearts ( Figure 6A ). This beneficial effect was also due to acceleration of glycogen synthesis (by 96%, P , 0.05) ( Figure 6B ) and a subsequent inhibition of glycolysis (by 49%, P , 0.05) ( Figure 6C) . Glucose oxidation was accelerated by SB (by 47%, P , 0.05) ( Figure 6D) , H þ production from glucose metabolism was reduced (by 58%, P , 0.05) ( Figure 6E) , while glucose uptake was unaltered (data not shown). Similar to our previous results, the reduction in H þ production during reperfusion resulted in a significant attenuation of Ca 2þ i overload ( Figure 6F ).
Discussion
The first evidence for the role of GSK-3 in cardioprotection was obtained in studies showing that ischaemic preconditioning results in phosphorylation and inhibition of GSK-3b and that pharmacological inhibition of GSK-3 mimics the cardioprotective effects of preconditioning. 4 Now, extensive evidence supporting the role of GSK-3 inhibition in ischaemic as well as various forms of drug-induced preconditioning and postconditioning is emerging (see reviews 28 -32 ) and GSK-3 is now attracting considerable research attention as it is considered to participate in a common final pathway of cardioprotection leading to inhibition of the opening of mPTP, and to improved cell survival. 12 Our demonstration that SB, administered either before ischaemia or at the onset of reperfusion, enhances recovery of postischaemic mechanical function confirms that drug-inhibition of GSK-3 is cardioprotective. 4, 17, 33 More importantly, this study provides new insights about mechanisms resulting from GSK-3 inhibition and indicates a role for altered glucose metabolism as an early and upstream event. Specifically, our data indicate that inhibition of GSK-3 increases glycogen synthesis during reperfusion which partially repartitions glucose-6-phosphate away from glycolysis. The reduced rate of glycolysis lessens intracellular acidosis during reperfusion and the potential for Na þ accumulation (via NHE) that leads to the observed attenuation of Ca 2þ i overload (via rmNCX). The reduced Ca 2þ i overload is potentially an upstream event leading to enhanced mitochondrial function during reperfusion and improved mitochondrial oxidative capacity. We also provide evidence that acceleration of glycogen synthesis is not a consequence of improved LV function, as similar metabolic alterations occur in glycogen-depleted aerobic hearts independent of changes in LV mechanical function.
In order to examine the relative rates of glycogen synthesis and glycolysis in the absence and presence of GSK-3 inhibition, studies were performed in isolated rat hearts that were perfused in working mode with both glucose and palmitate as energy substrates. These conditions ensure hearts are studied under conditions of physiological work load (energy demand) as well as adequate energy supply. Moreover, aerobic perfusion conditions ensure the re-establishment of normal glycogen content (previously severely depleted during deep anaesthesia and heart extraction), a key requirement for investigations of glucose and glycogen metabolism. Also, this experimental approach enables LV work to be measured simultaneously with rates of glucose, glycogen, and palmitate metabolism or with beat by beat analysis of d[Ca 2þ ] i and s[Ca 2þ ] i .
Consistent with previous reports 25, 34, 35 ischaemia results in significant Ca 2þ i accumulation in untreated hearts that only partially recovers during reperfusion and this is associated with partial recovery of LV mechanical function. The significant attenuation of Ca 2þ i overload by GSK-3 inhibition during reperfusion and the enhanced recovery of mechanical function are potentially direct results of inhibition of glycolysis, H þ production, and acidosis 36 that lessens Na þ accumulation and rmNCX activity. It is unlikely that GSK-3 and cardioprotection GSK-3 inhibition exerts its action via changes in SR Ca 2þ release, as no changes occur in the amplitude of Ca 2þ i transients. GSK-3 inhibition also reduces Ca 2þ i overload during ischaemia. This beneficial effect is independent of LV work, but as rates of glucose metabolism could not be measured during GI, the role of glucose metabolism in limiting Ca 2þ i overload during ischaemia cannot be determined. While alteration of glycolysis may be involved, other mechanisms arising from GSK-3 inhibition during ischaemia may contribute, such as improved ionic homeostasis due to reduced mitochondrial ATP consumption, an effect possibly due to interaction of GSK-3 with VDAC. 17 Our demonstration that cardioprotection was similar in hearts treated with SB either before ischaemia or at the onset of reperfusion suggests that the effect of GSK-3 inhibition on Ca 2þ i overload during ischaemia is unlikely to play an important role in the enhanced recovery of mechanical function during early reperfusion.
A clear association between stimulation of glycogen synthesis, partial inhibition of glycolysis, and attenuation of Ca 2þ i overload is demonstrable in hearts subjected to IR. However, as LV mechanical function (energy demand) and energy substrate metabolism are interdependent, additional experiments were performed in aerobic hearts in order to determine if alteration of glucose partitioning might simply be a consequence, rather than a cause, of enhanced recovery of LV function. The ability of SB to produce a similar re-partitioning of glucose metabolism in aerobic hearts that are partially depleted of glycogen to levels similar to the end of GI confirms that the alterations in metabolism are not a consequence of changes in LV function. Rather, it indicates that the enhanced recovery of LV function is due to the changes in metabolism.
Similar beneficial consequences of inhibition of H þ production from glucose metabolism have been reported previously 37 -39 and result mainly from reduced activation of the coupled exchangers, NHE, and rmNCX, that reduce Na þ i and Ca 2þ i accumulation, respectively, that lessens Ca 2þ i overload and LV mechanical dysfunction. 20 Other approaches that limit Ca 2þ i overload also reduce IR injury such as pharmacological inhibition or genetic ablation of NHE 34, 40, 41 or NCX. 42, 43 On the other hand, several studies have shown that prolongation of acidosis during reperfusion is cardioprotective. 44 -47 In order to assess the role of acidosis during reperfusion, it is important to distinguish between extracellular and intracellular acidosis. In those studies, reperfusion with acidic solution was utilized to prolong acidosis during reperfusion which reduces the transmembrane proton gradient and so will inhibit the activity of the Na þ /H þ exchanger, thereby limiting the exchange of intracellular H þ with extracellular Na þ . This will eventually limit Ca 2þ i overload. Partial inhibition of glycolysis and H þ production is an upstream event that hinders activation of NHE and subsequently rmNCX, thereby reducing dysregulation of myocardial ionic homeostasis. A well-described downstream consequence of GSK-3 inhibition is delayed opening of mPTP in response to reactive oxygen species. 12 The role of GSK-3 in limiting mPTP opening was proposed to arise by direct phosphorylation of VDAC and prevention of its binding to hexokinase, 13 but more recent studies indicate that VDAC is not required for mPTP formation and does not possess a regulatory role in mPTP opening. 15 Thus, the uncertain identity of the mPTP complex limits a clear interpretation of its interactions with GSK-3. However, direct interaction of GSK-3 with VDAC reduces adenine nucleotide transport across the outer mitochondrial membrane independent of mPTP opening, 17 thereby conserving ATP content by reducing mitochondrial ATP consumption. Such a preservation of ATP may facilitate ionic homeostasis and explain our observation that SB attenuates Ca 2þ i overload during ischaemia. However, it cannot explain cardioprotection when SB is administered only at the onset of reperfusion, a period when ATP generation returns close to pre-ischaemic levels. 48 Instead, we propose a cytosolic action of GSK-3 inhibition that may indirectly modulate mPTP opening, via reduced acidosis during reperfusion and attenuation of Ca 2þ i overload. Reintroduction of oxygen and restoration of the mitochondrial membrane potential during reperfusion, together with elevated Ca 2þ i levels, is expected to cause a significant Ca 2þ uptake into the mitochondria through the mitochondrial Ca 2þ uniporter. 49 As elevation of mitochondrial matrix Ca 2þ levels is an essential factor for mPTP opening, 50 the lower Ca 2þ i levels during reperfusion resulting from GSK-3 inhibition likely limits mPTP opening. Although the open probability of mPTP is reduced sharply in acidic pH in de-energized mitochondria, 51,52 exposure of respiring mitochondria to an acidic environment, such as in early reperfusion, will favour mitochondrial inorganic phosphate uptake that facilitates mPTP opening. 53 Thus, reduction in H þ production during reperfusion may limit mPTP formation. Thus, we propose that GSK-3 inhibition and the re-partitioning of glucose metabolism is an early and upstream event that leads to less Ca 2þ i overload and enhanced recovery of LV function. Reduced acidosis and attenuation of Ca 2þ i overload may ultimately lead to inhibition of mPTP opening and improved cell viability. This may also explain the improved mitochondrial function, demonstrated by enhanced glucose and palmitate oxidation, during reperfusion in SB-treated hearts. The stimulated mitochondrial oxidation may also arise due to the improved recovery of LV function and higher energy demand in SB-treated hearts. Furthermore, a direct interaction is unlikely as GSK-3 inhibition has no effect on mPTP opening in isolated mitochondria. 54 
Conclusion
Although GSK-3 was initially discovered and named for its role in regulating glycogen metabolism, this is the first study to link this important effect on myocardial metabolism with cardioprotection. Our study highlights the ability of GSK-3 to regulate myocardial glycogen and glucose metabolism and demonstrates an additional mechanism linking GSK-3 inhibition with enhanced recovery of post-ischaemic mechanical function. Inhibition of GSK-3 during reperfusion stimulates glycogen synthesis which repartitions glucose-6-phosphate away from the glycolytic pathway. The reduced rate of glycolysis lessens H þ production from glucose metabolism and subsequently reduces Ca 2þ i overload. These effects limit LV mechanical dysfunction in early reperfusion and may contribute to improvements in mitochondrial function and cell viability.
